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Abstract
Fenretinide is a synthetic retinoid characterized by anticancer activity in preclinical models and favorable toxicological
proﬁle, but also by a low bioavailability that hindered its clinical efﬁcacy in former clinical trials. We developed a new
formulation of fenretinide complexed with 2-hydroxypropyl-beta-cyclodextrin (nanofenretinide) characterized by an
increased bioavailability and therapeutic efﬁcacy. Nanofenretinide was active in cell lines derived from multiple solid
tumors, in primary spheroid cultures and in xenografts of lung and colorectal cancer, where it inhibited tumor growth
independently from the mutational status of tumor cells. A global proﬁling of pathways activated by nanofenretinide
was performed by reverse-phase proteomic arrays and lipid analysis, revealing widespread repression of the mTOR
pathway, activation of apoptotic, autophagic and DNA damage signals and massive production of dihydroceramide, a
bioactive lipid with pleiotropic effects on several biological processes. In cells that survived nanofenretinide treatment
there was a decrease of factors involved in cell cycle progression and an increase in the levels of p16 and
phosphorylated p38 MAPK with consequent block in G0 and early G1. The capacity of nanofenretinide to induce
cancer cell death and quiescence, together with its elevated bioavailability and broad antitumor activity indicate its
potential use in cancer treatment and chemoprevention.
Over the last decades, the use of targeted agents and
immunotherapeutics has increasingly ﬂanked classic
cytotoxics, leading to a signiﬁcant survival improvement
for selected subsets of cancer patients. Nevertheless, new
therapies are often associated to high economic burden,
toxic side effects and absence of predictive biomarkers of
efﬁcacy. Therapy failure in cancer patients is tightly linked
to the presence of tumor-initiating cells responsible for
drug resistance and cancer relapse1,2. Therefore, effective
therapeutic strategies should ideally be able not only to
kill cancer cells but also to prevent the reactivation of
remaining tumorigenic cells. Fenretinide (N-4-hydro-
xyphenyl-retinamide) is a synthetic derivative of all-trans
retinoic acid characterized by high cytotoxic efﬁcacy
against cancer cells in vitro and previously investigated as
a potential anticancer and chemopreventive drug3–11.
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Previous clinical phase I-III evaluations of fenretinide
have shown minimal systemic toxicity and good toler-
ability7,12,13, fostering additional studies aimed at
exploiting the selective anticancer effect of this com-
pound. However, clinical trials aimed at evaluating the
activity of fenretinide in cancer patients yielded frustrat-
ing results as therapeutic plasma levels could not be
attained due to the poor aqueous solubility and con-
sequent low bioavailability of the drug3,8,13. In fact plasma
concentrations of fenretinide remained below the mini-
mum threshold for the onset of the antitumor activity also
after multiple and protracted administrations3,13. For-
mulations aimed at increasing fenretinide bioavailability
were previously prepared by drug incorporation into lipid
matrices or oil-in-water emulsions. They showed an
improved performance compared to previous studies but
faced some problems related to the increase of the
administration dose and the correspondent increase in
plasma concentration14–17. We have prepared a new
fenretinide formulation characterized by improved aqu-
eous solubility through drug saliﬁcation and complexation
with 2-hydroxypropyl β-cyclodextrin, a solubilizing exci-
pient endowed with favorable biodistribution and reduced
toxicity18. The new fenretinide formulation (referred
thereafter as nanofenretinide, NanoFEN) showed high
anticancer efﬁcacy in vitro and in vivo against cell lines
from multiple tumors, primary spheroid cultures of lung
and colon cancer cells and tumor xenografts in the
absence of macroscopic toxic effects. A global analysis of
NanoFEN-activated events revealed a widespread inhibi-
tion of the mTOR pathway, cell death with mixed
autophagic/apoptotic features and cell cycle block with
induction of quiescence. Such events occurred in parallel
with a massive accumulation of bioactive dihydrocer-
amide lipids, pleiotropic inhibitors of cell cycle and
metabolism. Altogether, these results indicate that
NanoFEN activates a multifactorial program in cancer
cells composed by signals of apoptosis, autophagy and
proliferative/metabolic inhibition, resulting in a wide-
spread and durable antitumor effect. Although additional
studies will be required to establish the efﬁcacy and
absence of toxicity of NanoFEN in human subjects, our
results indicate this compound as a candidate for future
clinical studies.
Results
Generation of a new bioavailable fenretinide formulation
The extremely poor aqueous solubility of fenretinide
traditionally represents a strong drawback limiting the
bioavailability of this molecule and its use in anticancer
therapy. A possible solution for increasing fenretinide
bioavailability is its complexation with cyclodextrins, in
order to improve the drug aqueous solubility and provide
chemical stability. Compared to other solubilizing exci-
pients marketed in pharmaceutical products, cyclodex-
trins are endowed with favorable biodistribution and
reduced toxicity also after repeated administrations18.
However, the very low solubility of fenretinide in water
prevents its spontaneous inclusion into the hydrophobic
cavity of the cyclodextrin, compromising the effectiveness
of the complexation process. We overcame this obstacle
by rising the aqueous solubility of fenretinide through an
unprecedented procedure of fenretinide saliﬁcation that
allowed drug complexation to take place in the presence
of hydroxypropyl β-cyclodextrin (Fig. 1a). The formation
of the fenretinide-cyclodextrin complex is demonstrated
by the chemical shift changes in the nuclear magnetic
resonance (1H NMR) spectrum corresponding to protons
H8, H3, H5, H2, H6 of the complexed fenretinide (Fig. 1b,
right panel) with respect to the fenretinide salt (Fig. 1b,
left panel). Figure 1c reports the aqueous solubility of
NanoFEN, showing it is >1000 times higher than pure
fenretinide (PureFEN). Importantly, in order to provide an
effective antitumor activity, the NanoFEN complex should
be stable in aqueous body ﬂuids and ideally release its
active molecule only after accumulation in the tumor site,
behaving as an hydrophobic absorbing phase and
favouring accumulation by the enhanced permeability and
retention effect (EPR effect)19. Figure 1d shows that the
release of fenretinide from the complex takes place only in
the presence of an adsorbing hydrophobic phase while it
is suppressed in a plain aqueous environment, thus sup-
porting a productive use of this formulation in the anti-
tumor therapy. Pharmacokinetics and bioavailability of
NanoFEN in mice were assessed by comparing intrave-
nous administration of NanoFEN versus fenretinide con-
tained in the oral gelatin capsules provided by the
National Cancer Institute and previously used in the
majority of clinical trials, which contain fenretinide dis-
persed in corn oil and polysorbate-80 (referred thereafter
as NCI fenretinide). We compared intravenous adminis-
tration of NanoFEN versus oral administration of NCI
fenretinide (Fig. 1e, left), oral administration of NanoFEN
versus oral administration of NCI fenretinide (Fig. 1e,
center) and intravenous administration of NanoFEN ver-
sus intravenous administration of PureFEN (Fig. 1e, right).
The latter was dissolved in 10% ethanol and saline to
obtain drug solubilization, although this procedure could
not be applicable to human use due to the presence of
fenretinide precipitates. In all three cases, NanoFEN
provided signiﬁcantly higher drug exposure, being Area
Under the Curve (AUC) values obtained after NanoFEN
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administration always higher than those obtained with
other systems either by oral or intravenous route (Fig. 1e
and Table 1). Previous formulations of fenretinide used in
clinical trials were characterized by a favorable tox-
icological proﬁle, with side effects generally limited to
diminished dark adaptation and dermatologic disorders
even at high dosages7,12,13,20,21. In order to determine
whether NanoFEN may produce macroscopic side effects
in mice, we evaluated body weight, hepatic and
hematologic parameters in mice treated intravenously
with NanoFEN. Body weight, alanine transaminase (ALT),
aspartate transaminase (AST), bilirubin and hematologic
values at the end of the treatment were comparable to
controls, providing preliminary evidences on the absence
of systemic toxicity, hepatic damage and myelosuppres-
sion (Supplementary Fig. 1a–c). These results show that
the new physico-chemical properties of NanoFEN provide
a substantial increase in fenretinide plasma levels without
Fig. 1 Generation and analysis of a new bioavailable fenretinide formulation. a Tridimensional representation of fenretinide (yellow)
complexed with 2-hydroxypropyl-β-cyclodextrin (blue). b 1H NMR analysis of fenretinide salt (left panel) and fenretinide complex with cyclodextrin
(right panel). Chemical shift changes corresponding to protons H8, H3, H5, H2, H6 of the complexed fenretinide (right panel). c Solubility of PureFEN
and NanoFEN in water at 25 °C. d Release of fenretinide from NanoFEN in a plain aqueous environment (black squares, NanoFEN+Vehicle) or in the
presence of an absorbing phase (red diamonds, NanoFEN+Absorbing phase). Values represent mean ± SD of three independent experiments. **P <
0.01 from two-tailed t-test. e Plasma pharmacokinetic proﬁles of fenretinide after single administration of 5 mg/kg from different formulations: left
panel, NanoFEN i.v. (black circles) compared to NCI p.o. (grey circles); central panel, NanoFEN p.o. (black circles) compared to NCI p.o. (grey circles);
right panel, NanoFEN i.v. (black circles) compared to PureFEN i.v. (grey circles). Tables show the Cmax and AUC values of the relative graphs
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macroscopic side effects, although in-depth toxicological
analyses will be required to rule out potential organ-
speciﬁc toxicities.
NanoFEN-induced killing of cancer cells from solid tumors
Multicellular spheroid cultures derived from primary
tumors have been shown to constitute a reliable system
for drug testing as they provide a closer model of cancer
heterogeneity as compared to commercial cell lines22–25.
Primary spheroid cultures were derived from both lung
and colorectal cancer (CRC) patients, biobanked at early
passages after isolation, characterized for common genetic
mutations and validated for their ability to reproduce the
histology of the original tumor in mouse xenografts25,26.
We tested NanoFEN on twenty-one spheroid lines of CRC
and six spheroid lines of lung cancer, the latter being
representative of all the major histological tumor types
(adenocarcinoma, squamous cell carcinoma, large cell
neuroendocrine carcinoma). NanoFEN was able to induce
death of colon and lung spheroids, with the latter showing
a sensitivity related to tumor histotype (Fig. 2a and Sup-
plementary Fig. 2a, b), although an analysis on a larger
number of samples would be required to conﬁrm this
correlation. Notably, the sensitivity of colorectal spheroids
to NanoFEN was independent of the presence of common
mutations incompatible with anti-EGFR agents, suggest-
ing that patients not eligible for targeted therapies could
in principle beneﬁt from NanoFEN treatment. NanoFEN
was also tested on three ATCC CRC cell lines and nine
ATCC lung cancer cell lines, where it induced cell death
with higher IC50 as compared to primary spheroid lines
(Fig. 2b and Supplementary Fig. 2a, b). We reasoned that
the presence of 10% serum in the culture media of ATCC
lines may account for their lower sensitivity to NanoFEN
as compared to spheroid lines (which are grown in serum-
free media). Thus, we treated ATCC cells with NanoFEN
in the presence of 1% serum and noticed that the IC50
was affected in CRC cell lines but not in lung cancer cell
lines (Supplementary Fig. 2a, b). Thus, the differential
sensitivity of ATCC lines and of spheroid lines likely
depends on a combination of culture conditions and of yet
unidentiﬁed factors. Finally, we tested the effect of
NanoFEN on primary cultures of melanoma, breast can-
cer, glioblastoma and sarcoma, and on ATCC lines of
hematologic cancer cells. NanoFEN displayed a broad
spectrum cytotoxic effect on all the cells tested and par-
ticularly on primary cultures, which displayed IC50 values
ranging from 0.2 to 4.9 µM (Supplementary Fig. 2c–g).
These results suggest that NanoFEN interferes with
mechanisms shared by multiple tumors to inhibit cell
viability.
In vivo antitumor efﬁcacy of NanoFEN on lung and CRC
xenografts
We assessed the antitumor effects of NanoFEN com-
pared to conventional chemotherapeutic agents on lung
and CRC xenografts derived from four primary spheroid
lines by monitoring tumor growth during treatment and
the variation of tumor size after treatment withdrawal.
NanoFEN and chemotherapy treatment signiﬁcantly
inhibited tumor progression in lung squamous carcinoma
xenografts, lung adenocarcinoma xenografts (Fig. 3a, b
left) and CRC xenografts, the latter with or without
mutated KRAS (Fig. 3c, d left). After treatment interrup-
tion, xenografts were monitored for two additional weeks
in order to monitor the rate of tumor regrowth. While
xenografts treated with chemotherapy showed accelerated
growth rates after treatment cessation, NanoFEN-treated
xenografts grew signiﬁcantly slower, suggesting that
NanoFEN does not induce an enrichment of tumorigenic
cells (Fig. 3a–d right). Finally, we investigated the feasi-
bility of a prolonged treatment with NanoFEN in mice.
Mice bearing lung cancer xenografts were treated with
NanoFEN for 70 days, during which we observed an
Table 1 Main pharmacokinetic parameters of Fenretinide in CD1 female mice after administration of Nanofenretinide
by oral or intravenous route in comparison with the NCI capsules and pure Fenretinide administered at the same dose
(5mg/Kg fenretinide)
Pk parameters NanoFEN i.v. PureFEN i.v. NanoFEN p.o. NCI p.o. Units
AUC 0-last 13563.5 6420.32 9378.9 3201 h*ng/ml
AUC inf 13656.8 6574.35 9382.5 3209.7 h*ng/ml
Ke 0.094 0.088 0.106 0.089 1/h
HL 7.41 7.87 6.54 7.79 h
Tmax – – 4 2 h
Vd 3.9 6.52 – – L/kg
Cmax 6932.6 4134.77 730.06 298.13 ng/ml
Cl 0.366 0.574 – – L/hr/kg
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extended arrest of tumor growth without any animal
death or evident signs of toxicity (Supplementary Fig. 3a).
Such observations, if conﬁrmed in humans, could candi-
date NanoFEN as a compound suitable for long-term
treatments such as those aimed at preventing tumor
recurrence.
Targeted phospho-proteomics on NanoFEN-treated
primary cancer cells
We aimed to generate a comprehensive picture of
NanoFEN-induced changes in pathway activation by
Reverse-Phase Protein Array (RPPA), a high-throughput
technology based on the detection of proteins along with
their post-traslational protein modiﬁcations, e.g., cleavage
and phosphorylation27. To this end, we performed RPPA
using a selection of 72 antibodies (Supplementary Table 1)
on lung cancer spheroids left untreated or treated with
NanoFEN at the IC50 dose. RPPA analysis revealed a
NanoFEN-dependent modulation of multiple pathways
involved in cell proliferation and biosynthesis, cell cycle
inhibition, cell death and stemness. In detail, treatment
with NanoFEN was associated with down-modulation of
multiple components of the mTOR pathway, i.e.,
decreased levels of phospho-mTOR, phospho-eIF4G and
phospho-4EBP1 or proliferation pathway, i.e., decreased
levels of phospho-ERK 1/2; induction of cell death and
DNA damage response, i.e., increased amounts of cleaved
Caspase 7, cleaved PARP and phospho-H2A.Xγ and a
decrease of cell cycle-related factors, i.e., phospho-Aurora
A/B/C, phospho-CDC2, phospho-PLK1, phospho-
CDC25c, phospho-Histone H3 as well as increased levels
of p16 and of phospho-p38 MAPK, accompanied by a
Fig. 2 Effects of NanoFEN on lung and colorectal cancer cells. a Cell viability of CRC spheroid cells (CSCs) (left) and lung cancer spheroid cells
(LCSCs) (right) treated with NanoFEN at the indicated concentrations. b Cell viability of CRC commercial cell lines (left) and lung cancer commercial
cell lines (right) treated with NanoFEN at the indicated concentrations. Values represent mean ± SD of three independent experiments
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Fig. 3 (See legend on next page.)
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decrease of the stemness-related factor ALDH (Fig. 4a–c).
Altogether, these results indicate that NanoFEN affects
multiple cellular functions, whose readout endpoints
underwent individual validation, as detailed in the fol-
lowing sections.
Cell cycle and stemness inhibition by NanoFEN in lung and
colorectal cancer spheroid cultures
RPPA results indicated that NanoFEN modulated cell
cycle-related factors (Fig. 5a), potentially resulting in
growth slowdown and/or arrest. We conﬁrmed the effects
of NanoFEN on cell cycle factors by validating the
increase in total p16 levels and phospho-p38 MAPK, and
the decrease in phospho-Aurora A-B-C and phospho-
PLK1 by immunoblotting in NanoFEN-treated lung and
CRC spheroids (Fig. 5b). Then, we investigated whether
NanoFEN was able to induce growth arrest through the
use of the mVenus p27K− construct, which identiﬁes with
yellow-green ﬂuorescence the cells in G0 phase of the cell
cycle and in G0/G1 transition28. Lung and colorectal
spheroids were transduced with mVenus p27K−, treated
with NanoFEN and evaluated by ﬂow cytometry. Upon a
48 h treatment, NanoFEN signiﬁcantly increased the
number of Venus+ cells as compared with control cells
indicating a higher number of G0 and G0/G1 transition
cells, whereas chemotherapy strongly decreased Venus
levels (Fig. 5c), indicating that in these conditions the two
treatments have opposite effects of on the cell cycle. The
decrease in ALDH levels observed in RPPA experiments
prompted us to investigate whether NanoFEN would
decrease tumor stem cell content (Fig. 5d). Aldeﬂuor
activity increased with chemotherapy, according to several
studies showing that chemotherapeutic agents induce a
population of drug-tolerant stem cells29, but decreased in
NanoFEN-treated lung spheroids (Fig. 5e and Supple-
mentary Fig. 3b). In line with this observation, we detec-
ted a decrease of genes related to stemness and self-
renewal (NANOG, SOX2, POU5F1) upon NanoFEN
treatment and a parallel increase in chemotherapy-treated
cells (Fig. 5f) in lung spheroids. The TOP-GFP system
provides a functional evaluation of stem cell content in
CRC by recapitulating the expression of the Wnt target
TCF linked to GFP30. Thus, we investigated TOP-GFP
expression in vitro and in vivo upon NanoFEN treatment
in cells transduced with a TOP-GFP.mCherry vector.
NanoFEN signiﬁcantly reduced TOP-GFP expression
in vitro upon a short-term treatment (Fig. 5g). In vivo
treatment with chemotherapy or NanoFEN of xenografts
obtained with TOP-GFP-transduced CRC cells resulted,
as expected, in decreased tumor growth as compared to
controls (Fig. 5h). Importantly, analysis of TOP-GFP
content at the end of the treatment in relation to tumor
volume showed that the proportion of TOP-GFP+ cells
increased upon chemotherapy but decreased upon
NanoFEN treatment (Fig. 5i and Supplementary Fig. 3c).
Altogether, these observations indicate that NanoFEN is
able to induce a quiescent state and to decrease the
content of cells with stem-like features in lung and CRC.
Cell death pathways activated by NanoFEN in primary lung
and CRC spheroid cells
As shown by RPPA analyses, NanoFEN treatment
affects several factors involved in DNA damage, cellular
stress and apoptosis. To gain further insights into death-
related events activated by NanoFEN we validated and
extended RPPA results by immunoblotting in lung and
colon spheroids, thus conﬁrming NanoFEN-mediated
caspase activation and cleavage of apoptotic substrates
(Fig. 6a, b and Supplementary Fig. 4a). Pre-treatment with
the pan-caspase inhibitor zVAD-fmk (zVAD) did not
substantially inhibit NanoFEN-induced toxicity, suggest-
ing that caspase activity is dispensable for NanoFEN-
induced death (Fig. 6c), similarly to what has been
described for the classical formulation of fenretinide.
Because reactive oxygen species (ROS) generation has
been reported to occur upon fenretinide treatment in
different cellular systems31, we next investigated the
production of ROS in NanoFEN-treated lung and colon
spheroids. We detected a moderate increase in ROS levels
in both lung and CRC cells, as shown by H2-DCFDA
staining (Fig. 6d). The ROS scavenger N-acetyl-cysteine
(NAC) partially rescued NanoFEN-induced death in both
(see ﬁgure on previous page)
Fig. 3 Antitumor efﬁcacy of NanoFEN on lung and CRC xenografts. a Left panel, volume of xenografts derived from squamous cell carcinoma
lung cancer spheroid cell line 3 (LCSC3) treated with vehicle (black diamonds), NanoFEN (grey squares) and cisplatin (Cis) plus gemcitabine (Gem)
(blue circles); right panel, tumor variation after treatment withdrawal. b Left panel, volume of xenografts derived from adenocarcinoma lung cancer
spheroid cell line 5 (LCSC5) treated with vehicle (black diamonds), NanoFEN (grey squares) and Cis plus pemetrexed (Pem) (red circles); right panel,
tumor variation after treatment withdrawal. c Left panel, volume of xenografts derived from adenocarcinoma colorectal spheroid cell line 10 (CSC10)
KRAS mutated treated with vehicle (black diamonds), NanoFEN (grey squares) and oxaliplatin (OXA) plus 5-ﬂuorouracil (5FU) (green circles); right
panel, tumor variation after treatment withdrawal. d Left panel, volume of xenografts derived from adenocarcinoma colorectal spheroid cell line 20
(CSC20) KRAS wild type, treated with vehicle (black diamonds), NanoFEN (grey squares) and OXA plus 5FU (orange circles); right panel, tumor
variation after treatment withdrawal. Values represent the mean ± SEM of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001 from
one-way ANOVA and Bonferroni post-test
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lung and colon CSCs and reduced ROS levels (Fig. 6e and
Supplementary Fig. 4b) suggesting that ROS generation
plays a role in NanoFEN cytotoxicity, in line to what
reported in leukemic stem cells32. Since the repression of
the mTOR pathway that emerged from RPPA analyses is
known to promote autophagy, we investigated the pre-
sence of autophagy-related markers in lung and CRC
spheroids treated in vitro with NanoFEN. Interestingly,
we found in the majority (3 out of 4) of the spheroid lines
tested an increased expression of both LC3 and its
phosphatidylethanolamine conjugate (LC3-II), which is
recruited to autophagosomal membranes33 (Fig. 6f and
Supplementary Fig. 4c). We also observed that the
autophagy inhibitor 3-MA was able to counteract
NanoFEN-induced death (Fig. 6g), suggesting that
autophagy contributes to NanoFEN-induced death in
both lung and CRC cells.
Modulation of cellular metabolism by NanoFEN
Fenretinide treatment of cancer cells has been pre-
viously associated with the production of lipid second
messengers including ceramide, gangliosides (both
Fig. 4 RPPA analysis of pathways activated by NanoFEN in primary lung cancer spheroid cells (LCSCs). a Hierarchical clustering of RPPA
results obtained on six LCSCs derived from different histotypes and one commercial lung cancer cell line (H292) treated with the respective dose of
NanoFEN for 48 h: LCSC1 4.3 μM; LCSC2 3.8 μM and 1.9 μM; LCSC3 0.1μM and 50 nM; LCSC4 0.9 μM; LCSC5 4.2 μM; LCSC6 4.9 μM; H292 29 μM. The
color-coded values (high= yellow, average= black, cyan= low) in the heatmap correspond to normalized intensities of averaged sample replicates
(n= 3), standardized over the sample set analyzed (z score). A list of RPPA antibodies used here is reported in Supplementary Table 1. b Graphical
representation of the activated (colored) and repressed (grey) pathways emerged from RPPA analysis in LCSCs treated as described in (a).
Phosphorylation sites are outlined in green when they result in protein activation. c Table highlights the endpoints upregulated in control (white
panel) and treated (yellow panel) lung cancer cells as described in (a)
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involved in apoptosis induction) and dihydrocer-
amide34,35. Moreover, RPPA results showed a global
inhibition of the mTOR pathway (Fig. 7a) that was sub-
sequently conﬁrmed by immunoblotting (Fig. 7b and
Supplementary Fig. 5a), thus linking NanoFEN mechan-
ism of action to metabolism, biosynthesis and lipid
signaling networks. We assessed the effect of NanoFEN
on cellular lipids by liquid chromatography-mass spec-
trometry (LC-MS) in lung and CRC spheroid cultures,
revealing a massive accumulation of d18 dihydroceramide
in treated cells (Fig. 7c and Supplementary Fig. 5b) as
compared to other ceramides (Supplementary Fig. 5c–g).
Fig. 5 (See legend on next page.)
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Dihydroceramide production was previously shown to
elicit multiple biological effects in cancer cells such as G0/
G1 cell cycle arrest, impairment of mitochondrial function
and autophagy induction36–38, corresponding to the bio-
logical effects observed in NanoFEN-treated cells. These
observations suggest that NanoFEN (as was previously
shown for fenretinide) targets dihydroceramide desatur-
ase (DES), thus inducing dihydroceramide accumulation.
Accordingly, we observed a strong increase of sphinga-
nine (SA, the lipid mediator upstream of DES) both
in vitro in NanoFEN-treated lung and CRC cells (Fig. 7d)
and in vivo in lung cancer xenografts (Supplementary Fig.
6a). In order to determine the functional relevance of
dihydroceramide production in NanoFEN-treated cells we
used the serine palmitoyltransferase inhibitor myriocin,
which blocks de novo sphingolipid biosynthesis39. Pre-
treatment of spheroid lines with myriocin partially pro-
tected cells from NanoFEN-induced death, indicating an
active role of the sphingolipid pathway in mediating
NanoFEN effects (Fig. 7e). In line with an important role
of dihydroceramide in mediating NanoFEN effects, SA
and the DES inhibitor GT11 induced a dose-dependent
viability decrease in lung cancer spheroids (Supplemen-
tary Fig. 6b). By contrast, the glucosylceramide synthase
inhibitor 1-phenyl-2-palmitoylamino-3-morpholino-1-
propanol (PPMP) was unable to block NanoFEN-induced
death, indicating that the cytotoxic effects of NanoFEN
are determined by the accumulation of dihydroceramide
rather than by glucosylceramide/ceramide formation (Fig. 7f).
Finally, we ought to determine whether the sphingolipid
pathway would cooperate with repression of the mTOR
pathway in mediating NanoFEN-induced toxicity. To this
aim, we mimicked the effect of NanoFEN by treating
spheroids with both sphinganine and GT11 at low
doses. Additional treatment with the mTOR pathway
inhibitor rapamycin signiﬁcantly potentiated the toxic
effects of the SA/GT11 combination, indicating a coop-
erative effect of the two pathways in inducing cancer cell
death (Fig. 7g and Supplementary Fig. 6c). Western blot
analysis of key factors implicated in mTOR signaling
showed that the combined treatment with SA/GT11/
rapamycin effectively inhibited the mTOR pathway and
recapitulated NanoFEN-related events (Fig. 7h).
Discussion
In accordance to their multifaceted role in cell pro-
liferation, differentiation and death, retinoids have long
been studied for their chemopreventive and chemother-
apeutic effects in cancer patients, although their
mechanism of action has not been completely elucidated.
One of the most promising retinoid derivatives is fenre-
tinide, which has been extensively investigated in phase I-
III clinical trials, revealing long-term safety and toler-
ability but modest anticancer effects3,4,7–15,21,40–43. The
scarce efﬁcacy of fenretinide in previous clinical studies is
related to its low bioavailability, as even high-dose sche-
dules and multiple administrations did not provide
plasma concentrations sustained over time at the levels
required for a therapeutic activity3,8,10–13. We report here
that a nanoencapsulated form of fenretinide (previously
modiﬁed through a saliﬁcation procedure in order to
increase complexation effectiveness) has an enhanced
solubility and reaches signiﬁcantly higher plasma levels
than formulations previously used in clinical trials. The
mechanism of action of NanoFEN was analyzed in pri-
mary spheroid cultures of lung and CRC, thus providing a
comprehensive picture of protein and lipid pathways
activated in cancer cells. The results emerging from
proteomic and lipidomic analyses revealed a complex set
of molecular events activated by NanoFEN, resulting in a
(see ﬁgure on previous page)
Fig. 5 Effects of NanoFEN on cell cycle and stem-like features in vitro and in vivo on lung cancer spheroid cells (LCSCs) and CRC spheroid
cells (CSCs). a Schematic representation of cell cycle regulators activated (black) or repressed (grey) arised from RPPA analysis of LCSCs treated with
NanoFEN as described in Fig. 4a. b Immunoblot analysis of cell cycle regulators phospho-Aurora A-B-C, phospho-PLK1, p38, phospho-p38 and p16 on
LCSC6 (left panel) and CSC7 (right panel) untreated and treated with NanoFEN at the IC50 concentration (4.9 μM and 0.2 μM respectively) for 48 h.
c Flow cytometry analysis of mVenus p27K−-transduced LCSC6 (left panel) and CSC7 (right panel) untreated and treated with NanoFEN at the IC50
dose (4,9 μM and 0,2 μM respectively) for 48 h, Gem 25 μM and OXA 10 μM. Values represent mean ± SD of three independent experiments. **P <
0.01; ***P < 0.001 from two-tailed t-test. d Schematic representation of stem-like factors (repressed in grey) emerged from RPPA analysis of lung CSCs
treated as described in Fig. 4a. e Cytoﬂuorimetric analysis of Aldeﬂuor activity on LCSC6 treated with NanoFEN at IC50 dose and Gemcytabine 25 μM
for 48 h. Values represent mean ± SD of three independent experiments. **P < 0.01; ***P < 0.001 from two-tailed t-test. f qRT-PCR analysis of indicated
genes on whole tumor lysates derived from LCSC6 xenografts, untreated or treated with NanoFEN 30mg/Kg/week and Cis 3 mg/Kg/week and Gem
60mg/Kg/week (Cis+ Gem). Values represent mean ± SD of three independent experiments. *P < 0.05; **P < 0.01 from two-tailed t-test. g Flow
cytometry analysis of TOP-GFP.mc-transduced CSC7, untreated and treated with NanoFEN at the IC50 dose 0.2 μM and OXA 10 μM for 48 h. Values
represent mean ± SD of three independent experiments. **P < 0.01 from two-tailed t-test. h Volume of xenografts derived from CSC10 transduced
with TOP-GFP.mc untreated (black downward triangles) or treated with vehicle or treated NanoFEN 30mg/Kg/week (green upward triangles) and
OXA 5mg/Kg/week plus 5FU 12.5 mg/Kg/week (red squares). Values represent mean ± SEM three independent experiments. *P < 0.05; **P < 0.01
from one-way ANOVA and Bonferroni post-test. i Total stem cell content in tumor xenografts obtained as in (h), relative to the experiment shown in
Supplementary Fig. 3c. Values were calculated as tumor weight × percentage of TOP-GFP.mc positive cells/100. Values represent mean ± SD of three
independent experiments. *P < 0.05; ***P < 0.001 from two-tailed t-test
Orienti et al. Cell Death and Disease          (2019) 10:529 Page 10 of 19
Ofﬁcial journal of the Cell Death Differentiation Association
broad landscape of functional effects ranging from cell
death (with features of both autophagy and apoptosis) to
cell cycle arrest and to a generalized metabolic repression
mediated by inhibition of the mTOR pathway and massive
production of dihydroceramide. The effect of NanoFEN in
inducing growth arrest/quiescence is particularly inter-
esting in view of a potential use of this compound in
chemopreventive settings. In fact, maintaining tumor cells
Fig. 6 (See legend on next page.)
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(particularly those disseminated in distant organs) in a
prolonged and stable quiescent state is progressively
emerging as a potential therapeutic strategy aimed at
preventing tumor relapse44. In line with this hypothesis, a
combination of all-trans retinoic acid and 5-azacitidine
has been reported to induce a quiescent state in bone
marrow-disseminated cancer cells, supporting a role of
retinoids in promoting a long-term metastasis-free con-
dition45–47 and is currently being investigated in a clinical
trial (NCT03572387). If conﬁrmed in additional pre-
clinical and clinical studies, the low toxicity of NanoFEN
would allow prolonged treatment schedules aimed at
avoiding the reactivation of disseminated tumor cells and
subsequent tumor relapse, particularly in cancers subject
to late recurrences such as those of breast and prostate.
Moreover, it would be interesting to investigate the effect
of NanoFEN in retinoid-sensitive tumors such as some
hematological tumors as well as neuroblastoma, where the
increased bioavailability of NanoFEN may allow more
effective treatment schedules as compared to previous
clinical trials. In summary, the results reported in this
study indicate NanoFEN as a bioavailable fenretinide
formulation with broad-range inhibitory effects on cancer
cells that may ﬁnd a future use in several clinical settings.
Materials and methods
Cells, tissues, mice, antibodies, and reagents
Colon and lung cancer specimens were obtained from
patients undergoing surgical resection upon informed
consent and approval by the Sapienza-Policlinico
Umberto I Ethical Committee (RIF.CE: 410717/10/
2016). Spheroid cultures were established and validated as
previously described48,49. All the commercial cancer cell
line were purchased from the American Type Culture
Collection (ATCC, Manassas, VA, USA) or Sigma-Aldrich
(St. Louis, MO, USA) and cultured following manu-
facturer’s instructions. Fenretinide, N-(4-Hydroxyphenyl)
retinamide (code 65646-68-6) was purchased from Olon
(Milan, Italy). 2-hydroxypropyl-β-cyclodextrin (average
Mw ~1380), potassium hydroxide, 1-octanol, D2O,
DMSO-d6 were purchased from Sigma-Aldrich. Anti-
bodies used for RPPA and western blot were listed in
Supplementary Table 1. Oxaliplatin and 5-ﬂuorouracil
were from Teva Italia (Milano, Italy) gemcitabine and
cisplatin were from Selleckchem (Houston, TX, USA).
Aldeﬂuor assay was from STEMCELL Technologies
(Vancouver, Canada). Myriocin was purchased from
ENZO Life Science (New York, NY, USA), N-[(1R,2S)-2-
hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)
ethyl]octanamide (GT11) and Sphinganine from Avanti
Polar Lipids (Alabaster, AL, USA), Rapamycin from Sell-
eckchem, z-Val-Ala-DL-Asp-ﬂuoromethylketone (zVAD)
from BACHEM (Torrance, CA, USA), DL-threo-1-Phe-
nyl-2-hexadecanoylamino-3-morpholino-propanol-HCL
(PPMP) from Matreya (State College, PA, USA), N-
Acetyl-L-Cysteine (NAC) was purchased from Sigma-
Aldrich, 5-chloromethylﬂuoresceindiacetate (CMFDA)
was purchased from Molecular Probes (Eugene, OR,
USA). Anti-LC3 and anti-β-Actin antibodies were pur-
chased from Sigma-Aldrich; phospho-Aurora A (Thr288)/
Aurora B (Thr232)/Aurora C (Thr198) (D13A11), phos-
pho-PLK1, phospho-S6 ribosomal protein (Ser240/244)
and total S6 ribosomal protein (5G10), caspase3, caspase7,
caspase9, PARP, fodrin cleaved, phospho-p38 MAP kinase
(Thr180/Tyr182), mTOR, phospho-mTOR (Ser2448), 4E-
BP1(53H11), phospho-4E-BP1(Ser65) antibodies were
from Cell Signaling Technology (Danvers, MA, USA).
Anti-CDKN2A (p16) was from Biolegend (London, Uni-
ted Kingdom). Secondary anti-mouse and anti-rabbit
antibodies coupled to horseradish peroxidase were from
Bio-Rad (Hercules, CA, USA).
Preparation of fenretinide 2-hydroxypropyl-β-cyclodextrin
complex (NanoFEN)
The ﬁrst step of NanoFEN preparation involved fenre-
tinide saliﬁcation to raise its aqueous solubility to the
(see ﬁgure on previous page)
Fig. 6 Analysis of cell death pathways activated by NanoFEN in lung cancer spheroid cells (LCSCs) and CRC spheroid cells (CSCs). a
Schematic representation of RPPA endpoints involved in DNA damage, cell stress and apoptosis activated (black) in LCSCs treated with NanoFEN as
described in Fig. 4a. Phosphorylation sites are outlined in green when they result in protein activation. b Immunoblot analysis of cell death-related
proteins Caspase-9, 3, and 7, PARP and α-fodrin on LCSC6 (left panel) and CSC7 (right panel) untreated and treated with NanoFEN at IC50 dose (4.9
and 0.2 μM, respectively) for 48 h. c Cell viability of LCSC6 (left panel) and colon CSC7 (right panel) pretreated with zVAD 40 μΜ and then with
NanoFEN at IC50 dose (4.9 and 0.2 μM, respectively) for 48 h. Values represent mean ± SD of three technical replicates of a representative experiment
of two biological replicates. *P < 0.05 from two-tailed t-test. d Production of reactive oxygen species (ROS) was measured by ﬂow cytometer in LCSC6
(left panel) and CSC7 (right panel) untreated or treated with NanoFEN (4.9 and 0.2 μM, respectively) for 24 h and then with 5 μM of CM-H2DCFDA.
Values represent mean ± SD of three independent experiments. *P < 0.05 from two-tailed t-test. e Cell viability of LCSC6 (left panel) and CSC7 (right
panel) pretreated with N-acetyl-cysteine (NAC) 2 mM for 1 h and after with NanoFEN for 48 h (4.9 and 0.2 μM respectively). Values represent mean ±
SD of three technical replicates of a representative experiment. *P < 0.05; **P < 0.01 from two-tailed t-test. f Immunoblot analysis of autophagy-
related marker LC3 I-II on LCSC6 (left panel) and CSC7 (right panel) untreated and treated with NanoFEN at IC50 dose (4.9 and 0.2 μM, respectively) for
24 h. g Cell viability of LCSC6 (left panel) and CSC7 (right panel) treated with 3-Methyladenine (3-MA) 5 mM plus NanoFEN (4.9 and 0.2 μM,
respectively) for 24 h. Values represent mean ± SD of a three technical replicates of a representative experiment. *P < 0.05; **P < 0.01; ***P < 0.001
from two-tailed t-test
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extent required for complexation with cyclodextrins.
Saliﬁcation was carried out by dissolving fenretinide
(2 mol in 20mL ethanol containing a stoichiometric
amount of potassium hydroxide. The solvent was
removed in a rotary evaporator to obtain a solid red
residue of fenretinide potassium salt (4-HPRK). The salt
Fig. 7 (See legend on next page.)
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was physically mixed with 2-hydroxypropyl-
β-cyclodextrin at 1:10 w:wsalt:cyclodetrin ratio and grin-
ded to homogeneity. The physical mixture obtained was
dispersed in 30mL water, stirred at room temperature 6 h
in the dark and subsequently left at 4 °C overnight. After
this period the suspension was stirred again for 2 h at
room temperature, diluted with 20mL water and ﬁnally
ﬁltered through a 0.2 µm ﬁlter to eliminate any excess of
undissolved material. The ﬁltered solution was lyophilized
until the solid complex was obtained as an orange-red
homogeneous powder. The complex was analyzed by 1H-
NMR to detect the presence of chemical shift changes
with respect to the free drug as indicators of fenretinide
inclusion into the cyclodextrin hydrophobic cavity50. For
the analysis the complex was dissolved in D2O and the
fenretinide salt in DMSO-d6. The 1H-NMR spectra were
recorded by an Inova 600MHz High Resolution NMR
Spectrometer. The amount of fenretinide incorporated
into the complex was spectrophotometrically determined
in solutions obtained by dissolving known amounts of the
solid complex in a water:ethanol (1:1, v-v) mixture with
the aim to dissociate the drug from the complex and
maintain its solubilization in the aqueous phase in the
presence of ethanol. The hydro-alcoholic solutions were
analyzed for their fenretinide content at the maximum
wavelength of the fenretinide absorption (360 nm). The
aqueous solubility of fenretinide complexed with 2-
hydroxypropyl-β-cyclodextrin was measured in compar-
ison with the pure drug. Excess amounts of the complex
or pure drug were placed in water, stirred 12 h at 25 °C in
the dark to saturation of the aqueous phase and ﬁltered
through 0.2 µm ﬁlters. After ﬁltration the saturated
solutions were spectrophotometrically analysed at 360 nm
for their fenretinide content.
Release studies
Release studies of fenretinide from the complex were
carried out by placing saturated aqueous solutions of the
complex in a dialysis membrane bag (Mw cutoff 5KD),
allowing diffusion only to the free drug and not to the
complex. The membrane separated the saturated aqueous
solution of the complex from a receiving compartment
containing an aqueous buffer (PBS pH 7.4) and 1-octanol
(10:1v:v ratio) used to extract the drug diffused through
the dialysis membrane and to simulate the presence of
hydrophobic absorbing phases such as biomembranes51.
The release of the drug from the complex was evaluated
by a spectrophotometric analysis of the complex solution
in the releasing compartment at the maximum absorption
wavelength of fenretinide (360 nm) at appropriate time
points.
Pharmacokinetics studies
The experiments were performed in CD1 female mice,
7 weeks of age, (body weight 25 ± 2 g) obtained from
Envigo RMS SrL (Udine, Italy). Mice were maintained
under speciﬁc-pathogen-free conditions with constant
temperature and humidity, according to the institutional
guidelines of the Istituto Superiore di Sanità Animal Care
Committee. Animal experimentation was conducted in
conformance with the following laws, regulations, and
policies governing the care and use of laboratory animals:
Italian Governing Law (D. l. 26/2014; Authorization n.19/
2008-A issued March 6, 2008 by the Ministry of Health).
The pharmacokinetics of NanoFEN, administered by oral
or intravenous route, was investigated in mice receiving
the formulation at doses corresponding to 5mg/kg of
fenretinide. The intravenous administration was carried
out by injection in the tail vein of an intravenous bolus of
NanoFEN dissolved in water or PureFEN suspended in a
mixture of ethanol 10 % in saline as a comparison. For the
oral administration the mice were gavaged the with
NanoFEN dissolved in water or with the reconstituted
content of the NCI capules, i.e., fenretinide (100 mg) in
corn oil (704 mg) and Polysorbate 80 (60 mg) as a com-
parison. After the intravenous or oral treatments, a series
of blood samples were taken at 15 and 30min and at 1, 2,
4, 8, 10, 24 and 48 h. Blood was collected in heparinized
(see ﬁgure on previous page)
Fig. 7 NanoFEN inhibits cellular metabolism in lung cancer spheroid cells (LCSCs) and CRC spheroid cells (CSCs). a Schematic representation
of RPPA results of proliferative and biosynthetic pathways repressed (grey) in LCSCs treated with NanoFEN. b Immunoblot analysis of proteins
involved in metabolic process on LCSC6 (left panel) and CSC7 (right panel) untreated and treated with NanoFEN at IC50 dose (4.9 and 0.2 μM,
respectively) for 48 h. c Graphs represent NanoFEN effects on lipid metabolism by liquid chromatography-mass spectrometry (LC-MS) on LCSC6 (left
panel) and CSC7 (right panel). Values represents the fold over control of treated cells with NanoFEN (4.9 and 0.2 μM, respectively) for 24 h. d
Sphinganine peak intensity in LCSC6 (left panel) and CSC7 (right panel) treated with NanoFEN (4.9 and 0.2 μM, respectively) for 24 h. e Cell viability of
LCSC6 (left panel) and CSC7 (right panel) treated with Myriocin 1 μM plus NanoFEN (4.9 and 0.2 μM, respectively) for 48 h. Values represent mean ±
SD of three independent experiments. *P < 0.05, from two-tailed t-test. f Cell viability of LCSC6 (left panel) and CSC7 (right panel) treated with
glucosylceramide synthase inhibitor PPMP 10 μM plus NanoFEN (4.9 and 0.2 μM, respectively) for 48 h. Values represent mean ± SD of three
independent experiments. *P < 0.05, from two-tailed t-test. g Cell viability of LCSC6 (left panel) and CSC7 (right panel) treated with dihydroceramide
desaturase inhibitor (GT11) 0.5 μM plus sphinganine (SA) 2 μM plus mTOR pathway inhibitor Rapamycin 10 nM for 48 h. Values represent mean ± SD
of three independent experiments. *P < 0.05; ***P < 0.001, from two-tailed t-test. h Immunoblot analysis of mTOR pathway components mTOR,
phospho-mTOR, S6RP and phospho-S6RP on LCSC6 (left panel) and CSC7 (right panel) treated as in (g)
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tubes from the retro-orbital plexus of the mice under
isoﬂurane anesthesia. To obtain plasma, blood samples
were centrifuged at 4000 rpm for 10 min at 4 °C. The
samples were stored at −20 °C until analysis. The total
concentration of fenretinide in plasma of mice was
determined according to a method previously described52.
Brieﬂy, aliquot of 200 μl of each plasma sample was added
to 400 μl of Acetonitrile (CH3CN) containing 125 μg/mL
Butylated hydroxytoluene (BHT), and the mixture was
vortexed and centrifuged to pellet the precipitated pro-
teins. The recovered supernatants were analysed on a
liquid chromatograph (Perkin-Elmer, Norwall, CT) ﬁtted
with a C18 (50 mm× 2.0 mm, 5 μm) reverse-phase col-
umn and a C18 precolumn (Perkin-Elmer, Milan, Italy).
The mobile phase consisted of CH3CN:H2O:CH3COOH
(75:2:2, v:v:v) delivered at a ﬂow rate of 2 mL/min.
Detection was carried out with a Perkin-Elmer LC95
absorbance detector at 362 nm. N-(4-ethoxyphenyl)-reti-
namide (EPR) was used as internal standard. For the
quantitative evaluation, reference standard curves were
set up in control mouse plasma with different known
amounts of NanoFEN or PureFEN. The measured fenre-
tinide concentration-vs-time data were elaborated by
non-compartmental analysis (WinNonLin software v3) to
obtain the main pharmacokinetic parameters of
NanoFEN.
Animal procedures
All animal procedures were performed according to the
Italian national animal experimentation guidelines (D.
L.116/92) upon approval of the experimental protocol by
the Italian Ministry of Health’s Animal Experimentation
Committee (DM n. 292/2015 PR 23/4/2015). 6-week-old
female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice
were purchased from The Jackson Laboratory (Bar Har-
bor, Maine, USA) for colon and lung cancer xenografts.
Tumors were measured twice weekly by an external
digital caliper, and volumes were calculated using the
following formula: π/6 x d2 x D, where d and D represent
shorter and longer tumor measurements, respectively.
Drug treatments started when tumor volume was 50-
100mm3: mice were randomized in control and treatment
group and treated with NanoFEN 10mg/Kg/threeweekly/
intraperitoneally (IP), chemotherapeutic agent combina-
tions as cisplatin 3 mg/kg/biweekly/IP+pemetrexed
200mg/kg/biweekly/IP or cisplatin 3 mg/kg/biweekly/IP
+gemcitabine 60 mg/kg/biweekly/IP or 5-ﬂuorouracil
12,5 mg/Kg+oxaliplatin 5 mg/Kg/biweekly/IP. Control
animals were treated with vehicle only. Tumors were
measured at the indicated timepoints and mice were
monitored for signs of drug-induced toxicity and weighed
regularly. At the end of experiments, tumors were col-
lected and dissociated to obtain cell suspension for sub-
sequent studies or monitored to evaluate tumor growth
rate after treatment interruption. Relative tumor growth is
indicated as ratio of tumor volume at the indicated days
after drug suspension versus volume at the last day of
treatment. Animals were euthanized according to the
national Animal Welfare Guidelines.
Lentiviral infection
Primary spheroid cultures of colon and lung cancer cells
were stably transduced with mVenus-p27K−28 or TOP-
GFP.mCherry (purchased from Addgene, Cambridge,
MA, USA) using ProFection® Mammalian Transfection
System from Promega (Madison, Wisconsin, USA) fol-
lowing manufacturer’s instructions.
Metabolite extraction
Samples were extracted following the protocol by
D’Alessandro et al53. Samples were resuspended in
0.15 mL of ice cold ultra-pure water (18 MΩ) to lyse cells,
then the tubes were plunged into a water bath at 37 °C for
0.5 min. Samples were mixed with 0.6 mL of −20 °C
methanol and then with 0.45 mL chloroform. Subse-
quently, 0.15 mL of ice cold ultra-pure water were added
to each tube and then transferred to −20 °C for 2–8 h. An
equivalent volume of acetonitrile was added to the tube
and transferred to 4 °C for 20min. Samples were thus
centrifuged at 10,000×g for 10 min at 4 °C. Finally, sam-
ples were dried in a rotational vacuum concentrator (RVC
2-18—Christ Gmbh; Osterode am Harz, Germany) and
re-suspended in 200 µl of water, 5% formic acid and
transfer to glass auto-sampler vials for LC/MS analysis.
Rapid resolution reversed-phase HPLC
An Ultimate 3000 Rapid Resolution HPLC system (LC
Packings, DIONEX, Sunnyvale, USA) was used to perform
metabolite separation. The system featured a binary pump
and vacuum degasser, well-plate autosampler with a six-
port micro-switching valve, a thermostated column
compartment. Samples were loaded onto a Reprosil C18
column (2.0 mm × 150mm, 2.5 µm - Dr Maisch, Ger-
many) for metabolite separation. For lipids multi-step
gradient program was used. It started with 8% solvent A
(ddH20, 20 mmol L-1 ammonium formiate; pH 5) to 6%
solvent A for 3 min than to 2% solvent A for 35min and
ﬁnally to 100% solvent B (methanol) in 30 min. At the end
of gradient, the column was reconditioned with 8% sol-
vent A for 5 min.
Mass spectrometry analysis through microTOF-Q
Mass spectrometry analysis was carried out on an
electrospray hybrid quadrupole time of Flight mass
spectrometer MicroTOF-Q (Bruker-Daltonik, Bremen,
Germany) equipped with an ESI-ion source. MS analysis
was carried out capillary voltage 2800 V, nebulizer 45psi
and dry gas of 9 l/min, scan mode 100–1500m/z. Data
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were acquired with a stored mass range of 100–2000m/z.
Tandem mass spectrometry (MS/MS) is used for lipid
species structural characterization. Automatic isolation
and fragmentation (AutoMSn mode) was performed on
the four most intense ions simultaneously throughout the
whole scanning period (30 min per run). Calibration of
the mass analyzer is essential in order to maintain an high
level of mass accuracy. Instrument calibration was per-
formed externally every day with a sodium formate
solution consisting of 10 mM sodium hydroxide in 50 %
isopropanol, water, 0.1 % formic acid. Automated internal
mass scale calibration was performed through direct
automated injection of the calibration solution at the
beginning and at the end of each run by a 6-port divert-
valve.
Real time PCR
RNA from vehicle and treated xenografts was extracted
with TRIzol (Thermo Fisher Scientiﬁc, Waltham, Massa-
chusetts, USA) following manufacturer’s instructions.
1 µg of RNA were reverse transcribed with M-MLV
reverse transcriptase (Thermo Fisher Scientiﬁc) and 50 ng
of cDNA were used as template in the PCR reactions.
Speciﬁc probes used for NANOG (Hs04399610_g1), SOX
2 (Hs04260357_g1) and POU5F1 (Hs00999634_gH) were
all from Thermo Fisher Scientiﬁc. Normalization was
performed using β-actin (Hs00194899_m1) as reference.
Values were expressed in terms of 2−ΔΔCt where ΔΔCt=
ΔCt sample−ΔCt calibrator. ΔCt is the difference in
threshold cycles between the speciﬁc RNA target and
reference gene amplicons given by StepOne Plus Real-
Time PCR software by negative correlation with an
internal reference dye (ROX).
Reverse-phase protein array
For RPPA experiments, primary lung cancer spheroid
cells (LCSCs) and commercial lung cancer cell lines were
left untreated or treated with NanoFEN (IC50 con-
centration) as follows: LCSC1 (4.3 µM), LCSC 2 (1.9 and
3.8 µM) LCSC 3 (50 nM and 1 µM) LCSC 4 (0.9 µM)
LCSC 5 (4.2 µM) LCSC 6 (4.9 µM) H292 (29 µM). Fol-
lowing 48 h treatment of the six LCSCs and H292 com-
mercial cell line, cell pellets were promptly lysed in a
buffer containing T-PER reagent (Thermo Fisher Scien-
tiﬁc), 300 mM NaCl (J.T.Baker; Avantor Performance
Materials, Center Valley, PA), protease and phosphatase
inhibitors cocktails (Sigma-Aldrich) and stored at −80 °C.
In order to prepare protein samples for RPPA printing,
protein lysates were allowed to thaw on ice, their total
protein concentration was measured using the Bradford
reagent method (Thermo Fisher Scientiﬁc) and the
volume corresponding to 50 μg of total protein was used
to further dilute samples to a ﬁnal concentration of
0.5 mg/mL, as follows: 50% 2X Tris-Glycine SDS Sample
Buffer (Life Technologies Corporation, Carlsbad, CA), up
to 47.5% sample volume and T-PER reagent (Thermo
Fisher Scientiﬁc) and 2.5% Tris (2-carboxyethyl)phos-
phine hydrochloride (TCEP) reagent (Thermo Fisher
Scientiﬁc). RPPA lysates were boiled for 3 min and stored
at −80 °C until further processing. Prior to printing onto
nitrocellulose-coated slides (GRACE Bio-Labs, Bend, OR)
using a robotic arrayer (Aushon Biosystems, Billerica,
MA, USA), RPPA lysates were allowed to thaw up to
room temperature and boiled for an additional 3 min. All
samples were printed in technical triplicate as neat and 1:4
dilution pairs. Reference standard lysates, i.e., HeLa
+Pervanadate (Becton, Dickinson and Company, Franklin
Lakes, NJ, USA), A431+EGF (Becton, Dickinson and
Company), Jurkat+Etoposide (Cell Signaling Technology)
and Jurkat+Calyculin A (Cell Signaling Technology),
were printed in 10-point decreasing mixtures of treated to
untreated samples as positive and quality controls of
antibody staining. Each reference standard curve was
printed in technical triplicates at a ﬁnal concentration of
0.5 mg/mL. A selected subset of the printed microarray
slides were stained with Sypro Ruby Protein Blot Stain
(Thermo Fisher Scientiﬁc) to estimate sample total pro-
tein concentration and the remaining slides were stored
under desiccated conditions at -20 °C. Immediately before
antibody staining, printed slides were treated with 1X
Reblot Mild Solution (Chemicon, Burlington, MA, USA)
for 15 min, washed 2 × 5min with PBS and incubated for
2 h in blocking solution containing 2% I-Block (Applied
Biosystems, Foster, CA, USA) and 0.1% Tween-20 in PBS.
Immunostaining was carried out using a tyramide-biotin
signal ampliﬁcation kit (DAKO, Santa Clara, CA, USA).
Primary antibody binding was detected using a biotiny-
lated goat anti-rabbit IgG H+L (diluted at 1:7500; Vector
Laboratories, Burlingame, CA, USA) or rabbit anti-mouse
Ig (diluted at 1:10, DAKO) followed by streptavidin-
conjugated IRDye®-680LT ﬂuorophore (LI-COR Bios-
ciences, Lincoln, Nebraska, USA. Primary antibodies
undergo pre- and post-RPPA validation for single band
speciﬁcity by western-blot using complex cellular lysates.
Negative control slides, incubated only with secondary
antibody were included in each staining run. All Sypro
Ruby, i.e., per-spot total protein content,as well as
immunostained slides were scanned using a Tecan Power
Scanner™ (Tecan Group Ltd, Männedorf, Switzerland) at
5 μm resolution. Acquired images were analyzed
with MicroVigene v5.2, http://www.vigenetech.com/
MicroVigene.htm (VigeneTech Inc, Carlisle, MA, USA),
for spot detection, local and negative control background
subtraction, replicate averaging and total protein nor-
malization. RPPA data analysis was performed by means
of ‘R’ v3.5.0 https://www.R-project.org/ (R Foundation for
Statistical Computing) and ‘RStudio’ v1.1.414 https://
www.rstudio.com/ (RStudio), using the following installed
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packages:base, plyr, tidyverse, FactoMineR, factoextra,
RColorBrewer, Bioconductor and shiny. Custom ‘R’
scripts for slide quality control, internal standardization
and two-way hierarchical clustering (correlation distance
and complete method) are available upon request. A
detailed list of antibodies used for RPPA is available in
Supplementary Table 1.
Flow cytometry
For ﬂow cytometry analysis, primary lung and CRC
spheroid cultures transduced with the mVenus p27K−
and treated with NanoFEN, oxaliplatin or gemcitabine
were dissociated at a single cell level mechanically or with
TrypLE Express (Thermo Fisher Scientiﬁc) respectively.
Cells were resuspended at a concentration of 500.000
cells/mL of PBS/0.4% BSA/0.5M EDTA. The percentage
of Venus positive cells was analyzed with a FACSCanto
ﬂow cytometer (Becton Dickinson) equipped with a DIVA
software. 10 μg/mL 7-aminoactinomycin D (Sigma-
Aldrich) was used for dead cells exclusion. The same
procedure was applied for primary CRC spheroids trans-
duced with the TOP-GFP.mCherry construct treated with
NanoFEN, oxaliplatin and 5-ﬂuorouracil for in vitro and
ex vivo experiments.
Measurement of intracellular ROS levels
The intracellular generation of ROS was measured
using the oxidation-sensitive ﬂuorescent dye 5-
chloromethylﬂuorescein diacetate (CM-H2DCFDA), with
the conversion of CM-H2DCFDA to dichloroﬂuorescein
(DCF) assessed as previously described54. An equal
number of dissociated spheroid cells (2.5 × 105) were
seeded in 6-well cell culture plates. Brieﬂy, each cell line
was incubated with NanoFEN at IC50 concentration and
pre-treated for 1 h with the antioxidant N-Acetyl-Cysteine
(NAC). At different times, the cells were washed twice
with pre-warmed Phosphate Saline Buffer (PBS) and then
incubated in the same buffer containing 5 μM CM-
H2DCFDA with DMSO alone at 37 °C. The ﬂuorescence
intensity of DCF was measured at 527 nm emission
wavelength after excitation at 492 nm at 1 h intervals for
up to 48 h using a Flow Cytometer Accuri (Becton
Dickinson). An increase in ﬂuorescence intensity as
arbitrary units indicated the net generation of
intracellular ROS.
Western blotting
Immunoblotting was performed as previously descri-
bed55. Brieﬂy, whole cell extracts were obtained by incu-
bating the cells in lysis buffer supplemented with protease
and phosphatase inhibitor cocktail. Lysates concentration
was determined and equal amounts of proteins were
loaded on a 4–12% precast gel (Thermo Fisher Scientiﬁc)
and transferred to nitrocellulose membranes. Blots were
blocked with TBST 5% non-fat dry milk (Bio-Rad
Laboratories, Hercules, CA, USA) and incubated over-
night at 4 °C with primary antibodies (described in the
Antibodies and Reagents section) then incubated for
45min with secondary HRP-conjugated antibodies dis-
solved in TBST/1% BSA. Chemiluminescent signals were
detected with Amersham ECL prime or select western
blotting detection reagent (GE Healthcare Life Sciences,
Barrington, IL, USA). Images were taken and analyzed
with Bio-Rad ChemiDoc Imagers (Bio-Rad Laboratories).
Viability assay
Cell viability upon treatment with NanoFEN, zVAD,
NAC, 3-MA, Myriocin, PPMP, GT11, SA and Rapamycin
was determined by CellTiter-Glo luminescent cell viabi-
lity assay (Promega, Madison, WI, USA) according to the
manufacturer’s directions. Brieﬂy, lung and colorectal
spheroids were dissociated mechanically or with TrypLE
Express (Thermo Fisher Scientiﬁc) respectively and see-
ded 3 × 103 per well in 96-well plates (three replicates per
experimental point) in serum-free medium, and incubated
in a humidiﬁed atmosphere at 37 °C, 5% CO2. Cells were
treated with the respective compounds and analysed after
the appropriate time period as described in detail in Fig-
ure Legends. Luminescence was detected with a DTX880
multimode microplate reader (Beckman Coulter, Brea,
CA, USA).
Statistical analysis
Analyses were performed using GraphPad Prism ver-
sion 4.0 for Windows (GraphPad Software) with non-
paired double-tailed t-test (after verifying normal dis-
tribution of the population with Shapiro–Wilk test) or
with one-way ANOVA where appropriate. Results are
presented as the mean ± standard deviation (SD) or
standard error of the mean (SEM) where appropriate.
Statistical signiﬁcance is expressed as *P < 0.05; **P < 0.01
and ***P < 0.001.
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